(Q43754209)

26 November 2017

title

Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy (English)

1 reference

26 November 2017

1 reference

1 reference

E M Kirchner

1

1 reference

26 November 2017

M Ebsen

2

1 reference

26 November 2017

J Kirchner

3

1 reference

26 November 2017

D Theegarten

4

1 reference

26 November 2017

R Voigtmann

5

1 reference

26 November 2017

publication date

1 August 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

12

1 reference

26 November 2017

issue

8

1 reference

26 November 2017

page(s)

1169-1171

1 reference

Synchronous Hodgkin's disease and non-Hodgkin's lymphoma

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Non-Hodgkin's lymphoma following successful treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Hodgkin's disease following non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Pathology and "molecular histology' of Hodgkin's disease and the border to non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Morphological and immunohistochemical investigation of non-Hodgkin's lymphoma combined with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Is Hodgkin's disease a unique entity?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011628322057

7 January 2021

Identifiers

DOI

10.1023/A:1011628322057

1 reference

26 November 2017

1 reference